Brokers Issue Forecasts for TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright currently has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS and FY2027 earnings at $4.14 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million.

TARS has been the subject of several other research reports. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Guggenheim restated a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Finally, Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock opened at $44.48 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The business has a 50-day moving average price of $50.97 and a 200 day moving average price of $43.13. The firm has a market cap of $1.70 billion, a PE ratio of -11.67 and a beta of 1.01.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently bought and sold shares of TARS. Crowley Wealth Management Inc. purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. FMR LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $166,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.